FAM22D Inhibitors
FAM22D inhibitors are a diverse set of chemical compounds that target different aspects of cellular signaling to achieve the inhibition of FAM22D. Staurosporine, a broad-spectrum kinase inhibitor, potentially impedes FAM22D activity by preventing necessary phosphorylation events, which are often critical for protein function. Similarly, LY294002 and Wortmannin both act as phosphatidylinositol 3-kinase (PI3K) inhibitors; if FAM22D is functionally downstream of PI3K, these inhibitors would impede FAM22D by disrupting signaling through the PI3K/AKT pathway, crucial for many cellular functions including growth and survival. Rapamycin and Sorafenib further exemplify the strategy of indirect inhibition; Rapamycin by inhibiting mTOR, a central regulator of cell metabolism, and Sorafenib through its inhibition of RAF kinase, a component of the MAPK pathway, which may both be pathways regulating FAM22D function.
Additionally, compounds like SB203580, U0126, and PD98059 target the MAPK pathway at different points, with SB203580 inhibiting p38 MAP kinase, and U0126 and PD98059 targeting MEK1/2, which are upstream of ERK. These inhibitions could result in decreased FAM22D activity if it is part of or regulated by the MAPK signaling cascade. SP600125 and PP2, which inhibit JNK and Src family kinases respectively, would also lead to reduced FAM22D activity if JNK or Src pathways govern its function. Bortezomib, a proteasome inhibitor, could alter the turnover of FAM22D by preventing its degradation, hence indirectly affecting its functional levels. Imatinib's inhibition of BCR-ABL and c-KIT tyrosine kinases would similarly result in decreased FAM22D activity if these kinases are part of the regulatory network for FAM22D. Collectively, these inhibitors target a myriad of signaling pathways that, while not directly interacting with FAM22D, are instrumental in its regulation and function, thus achieving a state of inhibition through a complex network of cellular interactions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can inhibit a wide range of kinases involved in various signaling pathways. As FAM22D might be regulated by phosphorylation events, the inhibition of these kinases can lead to reduced activity of FAM22D by preventing its phosphorylation and subsequent activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K). If FAM22D is downstream of PI3K signaling, LY294002 would indirectly inhibit FAM22D activity by blocking the PI3K/AKT pathway, which is involved in cell survival and growth, processes that may involve FAM22D. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is a central molecule in regulating cell growth and metabolism. If FAM22D functions are linked to mTOR signaling, rapamycin would lead to inhibition of FAM22D activity by disrupting the pathway needed for its functional expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. If the activity of FAM22D is modulated by the p38 MAPK pathway, inhibition by SB203580 would indirectly lead to decreased activity of FAM22D by blocking the signaling events required for its activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of ERK in the MAPK pathway. Inhibition of MEK1/2 by U0126 would lead to reduced ERK activity, which could result in the indirect inhibition of FAM22D if FAM22D is part of this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. Similar to LY294002, if FAM22D activity is dependent on the PI3K pathway, then inhibition by wortmannin would lead to downstream inhibition of FAM22D's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which prevents the activation of MAPK/ERK. If FAM22D is regulated by the ERK pathway, PD98059 could inhibit FAM22D function indirectly by blocking the necessary signaling events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which influences cell proliferation and apoptosis. If FAM22D operates downstream of JNK, then inhibition by SP600125 could reduce the functional activity of FAM22D. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Since Src kinases can regulate various signaling pathways, if FAM22D is associated with Src-mediated signaling, PP2 could indirectly inhibit FAM22D activity through the inhibition of Src kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If FAM22D is regulated through proteasomal degradation, the inhibition of the proteasome by Bortezomib could lead to altered turnover and functional inhibition of FAM22D. | ||||||